Regeneron Pharmaceuticals (NASDAQ:REGN) : The total money flow in Regeneron Pharmaceuticals (NASDAQ:REGN) was negative ($5.04 million), which signals selling by the traders on Wednesdays session. They trimmed their holdings by selling the stock on downticks to the tune of $29.33 million. In comparison, the inflow of money into the stock on upticks was $24.29 million. The uptick to downtick ratio was 0.83. Similarly, the block trades show selling by large traders on strength. The value of stocks sold down on downtick was $0 million. The value of transactions on uptick was $3.44 million. The negative money flow of ($3.44 million) confirms the selling in Regeneron Pharmaceuticals (NASDAQ:REGN) on strength. Regeneron Pharmaceuticals (NASDAQ:REGN) gained $6.86 at $346.64, a gain of 2.02% over the previous days close. However, the stock registered 2.11% in the week.
In an insider trading activity,The director of Regeneron Pharmaceuticals Inc, Ryan Arthur F sold 1,000 shares at $396.64 on May 24, 2016. The Insider selling transaction had a total value worth of $396,640. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 10.4% of Regeneron Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.67% . Institutional Investors own 75.19% of Regeneron Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -3.67%.
The company shares have dropped -32.92% from its 1 Year high price. On Aug 4, 2015, the shares registered one year high at $605.93 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $377.04 and the 200 Day Moving Average price is recorded at $412.90. Regeneron Pharmaceuticals (NASDAQ:REGN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $343.28 and $342.42 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $351.20. The buying momentum continued till the end and the stock did not give up its gains. It closed at $347.86, notching a gain of 2.38% for the day. The total traded volume was 1,081,164 . The stock had closed at $339.78 on the previous day.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.